ABSTRACT Background Alcohol‐associated liver disease (ALD) is a leading indication for liver transplantation (LT) in the United States. While post‐transplant outcomes are well established, the relative survival benefit of LT compared to non‐LT remains underdefined. Methods Using Optum's de‐identified Clinformatics Data...
Wan-Zhu Tu, L. Nephew, Yi-Ning Li et al.· Alcohol, clinical & experime...· 0 citations
BACKGROUND AND AIMS
Polycystic ovary syndrome (PCOS) is the leading endocrine disorder in reproductive-age women. Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in women with PCOS, but they are underrepresented in MASLD therapeutic trials. We evaluated the safety and efficacy of saroglitazar...
Niharika R. Samala, J. González-González, Robert A. Jenders et al.· Hepatology· 0 citations
BACKGROUND AIMS
Idiosyncratic drug-induced liver injury (DILI) is an infrequent cause of liver disease. The aim of this study is to report on temporal changes in the etiology and outcomes of idiosyncratic DILI in the United States DILIN Prospective study.
METHODS
The presenting clinical features and outcomes of conse...
R. Fontana, N. Chalasani, P. Hayashi et al.· Hepatology· 0 citations
BACKGROUND & AIMS
Cirrhosis from metabolic dysfunction-associated steatotic liver disease (MASLD) usually develops with advancing age, yet a subset of patients presents at younger ages. We examined genetic and metabolic factors associated with younger-onset MASLD cirrhosis.
APPROACH AND RESULTS
Adults with biopsy-pro...
Veeral H. Ajmera, Linus Schwantes-An, Luis Antonio Díaz et al.· Clinical Gastroenterology an...· 0 citations
The genetic susceptibility to MASLD histological severity remains incompletely defined. We assessed the associations between recently developed genome‐wide association studies–derived polygenic risk scores (PRSs) and advanced fibrosis in MASLD. We also evaluated PRSs' associations with histological activity and selecte...
S. Gawrieh, Jing-Yi Tan, Xiu-Qing Guo et al.· Liver international (Print)· 0 citations
Background: Fibrosis development in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) is a key indicator of disease progression and clinical outcome. Bulk and single-cell transcriptomics on human tissue have advanced understanding of fibrosis progression, but interstudy heterogeneity and li...
Jessica L. Maiers, Tie-Bing Liang, Tingbo Guo et al.· Hepatology Communications· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.